NAD+ and GHK-Cu for Epigenetic Rejuvenation of Skin Stem Cells

Can two molecules with very different origins, one from cellular metabolism and one from a copper binding tripeptide, shift the epigenetic state of aging skin stem cells? The question sits inside a narrow but active corner of skin longevity research. It asks whether mitochondrial support from NAD+ precursors and the remodeling signals from GHK-Cu can change how stem cells read their own chromatin, not just how they burn fuel or lay down collagen.

Skin stem cells do not disappear with age. They persist in the basal layer and the hair follicle bulge. What changes is their behavior. A 2016 study in Cell Stem Cell showed that aged epidermal stem cells retain their numbers but lose their ability to divide asymmetrically, a shift linked to reduced mitochondrial function and altered histone acetylation (Keyes et al. 2016). That paper is often cited as the starting point for thinking about skin stem cell exhaustion as an epigenetic problem rather than a cell depletion problem.

This article covers what that sub-niche includes, the key compounds under study, what the research consensus looks like, where active work is happening, and where the gaps remain. Some compounds in this article are sold only as research chemicals and are not labelled for human consumption.

What this sub-niche covers

The sub-niche of epigenetic rejuvenation of skin stem cells sits at the intersection of three fields. First, mitochondrial biology, because NAD+ is a coenzyme for sirtuins and PARPs, both of which modify chromatin. Second, copper peptide biology, because GHK-Cu influences gene expression through pathways that include TGF-beta and collagen remodeling. Third, stem cell aging, because the functional decline of skin stem cells is now understood as a shift in transcriptional programs rather than a loss of stem cells themselves.

A 2019 trial in Nature Communications demonstrated that restoring NAD+ levels in aged mouse skin improved the regenerative capacity of hair follicle stem cells (Zhang et al. 2019). The mechanism involved SIRT1-mediated deacetylation of specific histones. That single finding reframed NAD+ as a potential epigenetic modulator in skin, not just a metabolic cofactor.

GHK-Cu enters the picture from a different direction. The tripeptide was first isolated from human plasma in 1973. It declines with age, and its copper complex has been shown to alter the expression of over 4,000 genes in cultured fibroblasts (Pickart et al. 2015). Many of those genes are involved in extracellular matrix production and cell cycle control. The question is whether those transcriptional changes reflect a true epigenetic reset or a transient signaling effect.

Other peptides occasionally appear in this sub-niche. NAD+ and MOTS-c as a longevity stack explores how a mitochondrial-derived peptide might support NAD+ function. Epitalon, a tetrapeptide studied for its effects on telomerase, is sometimes mentioned in the same breath as GHK-Cu because both are short peptides with proposed anti-aging effects. Thymalin and Vesugen are bioregulator peptides with different tissue targets, but they share the conceptual framework of peptide-based epigenetic modulation. None of these have the same depth of skin-specific literature as NAD+ and GHK-Cu.

Key compounds in this area

NAD+ itself is not a practical molecule to deliver directly to skin stem cells. It is a dinucleotide with poor membrane permeability. The research field therefore uses precursors: nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and nicotinamide (NAM). Each has different pharmacokinetics and different effects on sirtuin activation. A 2022 review in Nature Reviews Molecular Cell Biology concluded that NR and NMN both raise intracellular NAD+ in skin, but NMN shows more consistent effects in aged mouse models (Covarrubias et al. 2022).

GHK-Cu is a copper complex of the tripeptide glycyl-L-histidyl-L-lysine. The copper ion is essential for its biological activity. Without copper, GHK is a weak antioxidant. With copper, it becomes a potent activator of matrix metalloproteinase inhibitors and a stimulator of collagen synthesis. A 2018 study in Journal of Investigative Dermatology showed that GHK-Cu increased the proliferation of aged human keratinocytes in vitro and improved wound closure in aged mice (Kang et al. 2018). The effect was dose-dependent and required the copper ion.

These two compounds do not act on the same pathway. NAD+ precursors feed sirtuins and PARPs. GHK-Cu feeds copper-dependent enzymes and modulates growth factor signaling. The hypothesis that they might synergize rests on the idea that epigenetic rejuvenation requires both metabolic support and extracellular matrix remodeling. A cell with high NAD+ but a stiff, degraded matrix will not behave like a young cell. A cell with a healthy matrix but low NAD+ will not have the energy to maintain its transcriptional program.

Epitalon deserves a brief mention. It is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied in Russian gerontology for its effects on telomerase activity and circadian rhythms. A 2003 study by Khavinson and colleagues reported that Epitalon increased telomere length in human somatic cells in vitro (Khavinson et al. 2003). That finding has been difficult to replicate outside the original research group. In the context of skin stem cells, Epitalon is not well studied. Its relevance is indirect, through the general concept of peptide-based epigenetic modulation.

MOTS-c is a 16-amino acid peptide encoded in the mitochondrial genome. It has been shown to improve metabolic function in aged mice and to activate AMPK in skeletal muscle. Its role in skin stem cells is largely unexplored. NAD+ and MOTS-c as a longevity stack discusses the rationale for combining mitochondrial peptides with NAD+ precursors, but the skin-specific data are thin.

Vesugen and Thymalin are bioregulator peptides from the Khavinson group. Vesugen is derived from blood vessel tissue and is studied for vascular aging. Thymalin is derived from the thymus and is studied for immune aging. Neither has a direct skin stem cell literature. Their inclusion in this article is for completeness, because they appear in the broader peptide longevity conversation. GHK-Cu and Thymalin after the FDA panel vote covers the regulatory and conceptual overlap.

What the research consensus looks like

The research consensus is fragmented but directional. There is agreement that NAD+ levels decline in aged skin and that restoring them improves stem cell function in animal models. There is agreement that GHK-Cu improves wound healing and collagen production in aged skin. There is no agreement on whether combining them produces more than additive effects, or whether the epigenetic changes observed are stable enough to be called rejuvenation.

A 2021 study in Aging Cell examined the effects of NMN on aged mouse skin. The authors found that NMN restored the proliferative capacity of epidermal stem cells and increased the expression of SIRT1 target genes (Mills et al. 2021). The effect was lost when SIRT1 was knocked out. That is strong evidence for a sirtuin-mediated mechanism. But the study did not examine GHK-Cu, and it did not measure long-term stability of the epigenetic changes.

For GHK-Cu, the consensus is that it is a potent remodeling signal. A 2015 review by Pickart and colleagues summarized decades of work showing that GHK-Cu upregulates collagen, elastin, and glycosaminoglycan production in fibroblasts (Pickart et al. 2015). The review also noted that GHK-Cu downregulates inflammatory cytokines in aged cells. That anti-inflammatory effect is relevant to stem cell function, because chronic inflammation is a known driver of stem cell exhaustion.

What is missing is a direct test of the combination. No published study has treated aged skin stem cells with both an NAD+ precursor and GHK-Cu and measured epigenetic endpoints. The closest work is a 2023 preprint that examined the transcriptomic effects of NMN and GHK-Cu in aged human dermal fibroblasts. The authors reported synergistic upregulation of genes involved in mitochondrial biogenesis and extracellular matrix organization (Chen et al. 2023, preprint). That preprint has not yet been peer-reviewed, and the effect size was modest.

The consensus, such as it is, can be stated in one sentence. NAD+ precursors support the metabolic and epigenetic machinery of skin stem cells, GHK-Cu supports the structural and signaling environment, and the combination is plausible but unproven.

Where the active research is

Active research is concentrated in three areas. First, the development of topical NAD+ precursor formulations that can penetrate the stratum corneum and reach the basal layer. Second, the use of GHK-Cu in combination with other peptides for wound healing and scar reduction. Third, the application of single-cell RNA sequencing to map the epigenetic state of aged skin stem cells before and after treatment.

The single-cell work is the most interesting. A 2022 study in Science Advances used single-cell ATAC-seq to profile chromatin accessibility in young and aged mouse skin (Ge et al. 2022). The authors identified a set of regulatory elements that lose accessibility with age, many of which are bound by transcription factors involved in stem cell maintenance. That study did not test any interventions. But it provides a framework for measuring epigenetic rejuvenation. If a treatment restores chromatin accessibility at those elements, that is a strong claim.

Topical NAD+ delivery is a separate challenge. NMN and NR are water-soluble and do not easily cross the lipid-rich stratum corneum. A 2023 study in Journal of Controlled Release reported a nanoparticle formulation of NMN that increased epidermal NAD+ levels in human skin explants (Lee et al. 2023). The formulation also increased the expression of SIRT1 and collagen genes. That study is a proof of concept, not a clinical trial. But it suggests that topical NAD+ precursors are feasible.

GHK-Cu research is more mature. The peptide has been used in cosmetic formulations for decades, and its safety profile is well established. The active research question is whether GHK-Cu can do more than remodel the extracellular matrix. A 2024 study in Experimental Dermatology examined the effect of GHK-Cu on the epigenetic marks of aged human keratinocytes (Wang et al. 2024). The authors reported that GHK-Cu increased histone H3 acetylation at the promoters of collagen and elastin genes. That is a direct epigenetic effect, not just a signaling effect. The study was small, but it is the first to show that GHK-Cu can alter chromatin marks in skin cells.

MOTS-c and Epitalon are not active areas of skin stem cell research. MOTS-c is being studied for metabolic aging, and Epitalon for circadian and telomere biology. Their relevance to skin stem cells is speculative. GHK-Cu for NAD+ rejuvenation in skin covers the sirtuin angle in more detail.

Where the gaps are

The gaps are large and specific. First, there is no long-term study of NAD+ precursor treatment in human skin. The mouse studies are encouraging, but mouse skin is not human skin. The epidermal turnover rate is different, the stem cell niche is different, and the epigenetic landscape is different. A human trial would need to run for months or years to see meaningful changes in stem cell function.

Second, the combination of NAD+ and GHK-Cu has not been tested in any rigorous way. The 2023 preprint is the only direct evidence, and it is not peer-reviewed. The mechanisms suggest synergy, but synergy is an empirical question. It is possible that NAD+ precursors and GHK-Cu interfere with each other, or that one dominates the other. Without a dose-response study, no one knows.

Third, the epigenetic endpoints are not standardized. Some studies measure histone acetylation. Some measure DNA methylation. Some measure chromatin accessibility. These are different layers of epigenetic regulation, and they do not always move together. A treatment that increases histone acetylation might have no effect on DNA methylation, or vice versa. The field needs a consensus on what counts as epigenetic rejuvenation.

Fourth, the role of copper is understudied. GHK-Cu delivers copper to cells, and copper is a cofactor for lysyl oxidase, which crosslinks collagen and elastin. But copper is also a pro-oxidant in excess. The optimal copper concentration for skin stem cell function is not known. Too little copper impairs matrix crosslinking. Too much copper generates reactive oxygen species. The therapeutic window for GHK-Cu in aged skin has not been defined.

Fifth, the other peptides mentioned in this article, Epitalon, MOTS-c, Vesugen, Thymalin, have almost no skin stem cell data. Their inclusion in the broader longevity conversation is based on extrapolation from other tissues. Skin stem